So, this study has been conducted as a basic pharmacoeconomic simulatory analysis to assess the cost escalation and risk reduction, with additional safety, which would be expected if SGLT-2 and DPP-IV inhibitors were hypothetically substituted as add-on drugs in prescriptions of T2DM patients with ASCVD, HF, and/or CKD or those who are clinically judged to be at high risk for the same due to presence of multiple risk factors. This evidence concerns the gene SLC5A2 and atherosclerosis.